• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Allogeneic Tumor-reactive NK Cell Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Tumor-reactive NK Cells

Natural killer (NK) cells have attracted significant interest in cancer therapy due to their potent ability to identify and kill cancer cells in the body. NK cell-based cell therapy offers several advantages, including minimal side effects, the potential for off-the-shelf therapies from healthy donors, and the ability to target a wide range of cancer types. Recent studies have shown that PD-L1-expressing NK cells exhibit increased cytotoxicity against tumor cells and improved anti-tumor responses. Creative Biolabs is dedicated to advancing NK cell-based cell therapies for cancer treatment. Our experts are developing tumor-reactive NK cell therapy by leveraging the natural cytotoxic capabilities of NK cells along with the enhanced activity conferred by PD-L1 expression. Our tumor-reactive NK cells are engineered to express soluble IL15 (sIL15) and induced PD-L1 protein.

Allogeneic Tumor-reactive NK Cell Platform

Creative Biolabs is actively exploring the potential of allogeneic NK cell therapy to provide readily available treatments for patients without the need for individual customization. Our team of scientists focuses on allogeneic tumor-reactive NK cell therapy, utilizing NK cells derived from healthy donor cord blood for the development of "off-the-shelf" therapeutic solutions. Through retroviral transduction, we design NK cells to express IL-15. Additionally, NK cells undergo further cytokine activation to induce PD-L1 expression, ultimately enhancing their anti-tumor capabilities. These strategies aim to enhance the anti-tumor activity of NK cells.

Our allogeneic tumor-reactive NK cells exhibit some key features that make them ideal candidates for cell therapy in cancer treatment. These characteristics make tumor-reactive NK cells a promising option for use in cell therapies aimed at combatting cancer.

• High Levels of Activating Receptors: Tumor-reactive NK cells express a high level of activating receptors on their surface, such as NKG2D, NKp30, and NKp44, which enable them to recognize and target cancer cells more effectively.
• PD-L1 Expression: PD-L1 expression in NK cells is associated with higher activity and resistance to exhaustion.
• Secretion of IL-15: NK cells that secrete Interleukin-15 (IL-15) have been found to exhibit enhanced anti-tumor activity. IL-15 helps in the proliferation, survival, and function of NK cells, contributing to their potent anti-cancer effects.

Working with Creative Biolabs

Creative Biolabs specializes in the development of allogeneic tumor-reactive NK cell therapy for research purposes. We have a team of expert scientists and researchers who are dedicated to advancing the field of NK cell therapy through innovative research and development. Our services include cell isolation, optimization of cell culture conditions, cell engineering, characterization of NK cells, and preclinical testing of allogeneic NK cell therapies. By leveraging our comprehensive platform and expertise, clients can accelerate their research and development timelines. contact us to learn more about our allogeneic tumor-reactive NK cell therapy development services.

Reference

1. Nishiwaki, Manami, et al. "Immortalization of human hepatocytes from biliary atresia with CDK4R24C, cyclin D1, and TERT for cytochrome P450 induction testing." Scientific Reports 10.1 (2020): 17503.